万孚生物(300482) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥515,782,939.70, a decrease of 22.18% compared to the same period last year[12]. - The net profit attributable to shareholders for Q3 2023 was ¥65,307,986.60, an increase of 5.38% year-on-year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥41,827,818.23, a slight decrease of 0.31% compared to the previous year[12]. - The company reported a significant decrease in total operating income for the year-to-date period, amounting to ¥2,004,422,655.85, down 57.32% year-on-year[18]. - The net profit for the third quarter of 2023 is approximately ¥397.69 million, a decrease from ¥1.23 billion in the same period last year, representing a decline of about 67.7%[21]. - The total profit for the quarter is reported at ¥459.49 million, down from ¥1.43 billion year-over-year, indicating a decrease of approximately 67.8%[21]. - The company's operating profit stands at ¥462.77 million, significantly lower than ¥1.44 billion in the previous year, reflecting a decline of around 67.8%[21]. - The other comprehensive income attributable to the parent company is ¥2.22 million, down from ¥10.89 million in the previous year, reflecting a decline of about 79.6%[21]. - Basic and diluted earnings per share decreased from CNY 2.81 to CNY 0.91, a decline of approximately 67.7%[36]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥5,767,049,634.88, down 8.48% from the end of the previous year[12]. - Total non-current assets decreased from CNY 2,950,749,799.06 to CNY 2,611,242,678.16, a reduction of approximately 11.5%[32]. - Total assets decreased from CNY 6,301,138,498.06 to CNY 5,767,049,634.88, reflecting a decline of about 8.5%[33]. - The total liabilities decreased from CNY 1,763,580,723.22 to CNY 1,022,610,803.14, a reduction of approximately 42.0%[33]. - Current liabilities decreased significantly from CNY 1,141,054,967.76 to CNY 347,878,783.27, a decrease of approximately 69.5%[32]. Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥36,263,870.38, a decline of 103.37% year-on-year[12]. - Net cash flow from operating activities turned negative at CNY -36,263,870.38 compared to a positive CNY 1,076,944,403.73 in the previous period[37]. - Cash inflow from financing activities totals $51,683,680.83, a decrease from $279,485,215.78 in the previous period, reflecting a decline of about 81.5%[40]. - Cash outflow from financing activities is $470,649,566.21, up from $214,120,237.95 in the previous period, indicating an increase of approximately 120.4%[40]. - The company reported a net cash decrease of $428,112,939.92 for the current period, compared to a decrease of $771,536,348.19 in the previous period[40]. Investments and Expenses - The company experienced a 36.96% decrease in cash and cash equivalents, totaling ¥732,820,331.18, primarily due to investments in financial products[18]. - The company’s development expenses increased by 34.75% to ¥69,750,299.34, attributed to increased product registration and development costs[18]. - The company reported a 60.48% increase in financial income, amounting to ¥15,191,469.21, due to higher interest income from bank deposits[18]. - Research and development expenses for the current period are $259,473,251.75, down from $309,398,871.02 in the previous period, representing a decrease of about 16.1%[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 55,265, with the top ten shareholders holding a significant portion of the shares[25]. - The company has a significant shareholder relationship, with the controlling shareholders holding a combined 33.17% of the total shares[28].